AMBP and kidney injury: This phase 2b study, POINTER, aims to confirm the efficacy signal observed in the previous phase 2a (proof-of-concept) AKITA study, which assessed the efficacy of RMC-035 – a modified human therapeutic A1M protein – in preserving renal function in cardiac surgery patients at high risk for kidney injury.